Top

Published in:

01-03-2021 | Metastasis | Invited Commentary

We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases

Authors: Aslam Ejaz, Timothy M. Pawlik

Published in: World Journal of Surgery | Issue 3/2021

Excerpt

We read with great interest the recent manuscript by Nassar et al. [1] describing the results of a multi-institutional national survey on the management of patients with metachronous resectable colorectal liver metastases. We commend the authors for addressing a very common oncologic conundrum regarding the timing and choice of therapy for this patient population. We agree that expert opinion does play an important role in developing consensus for treatment strategies, particularly in situations where there are limited evidenced-based data to support practice. We do wish, however, to highlight several concerns regarding the survey and methodology that limited the generalizability and applicability of the survey results. …

Nassar A, Phelip JM, Goéré D et al (2020) What is the best therapeutic strategy for metachronousresectable colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy? A multidisciplinary inter-group survey. World J Surg. https://doi.org/10.1007/s00268-020-05837-zCrossRefPubMed

Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J ClinOncol 24(13):2065–2072CrossRef

Khoo E, O’Neill S, Brown E, Wigmore SJ, Harrison EM (2016) Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB 18(6):485–493CrossRef

Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN (1999) Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 126(2):178–183CrossRef

El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L (2014) Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book: e461–466

Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN guidelines insights: colon cancer, version 2.2018. J NatlCompr Cancer Network: JNCCN 16(4):359–369CrossRef

Bridgewater JA, Pugh SA, Maishman T et al (2020) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21(3):398–411CrossRef

Title: We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases
Authors: Aslam Ejaz
Timothy M. Pawlik
Publication date: 01-03-2021
Publisher: Springer International Publishing
Keywords: Metastasis
Bevacizumab
Cetuximab
Cytostatic Therapy
Published in: World Journal of Surgery / Issue 3/2021
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-020-05894-4

At a glance: The STEP trials

Springer Medicine

We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2021

A Review of Parathyroid Surgery for Primary Hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS)

Bi-national Review of Phaeochromocytoma Care: Is ICU Admission Always Necessary?

Author’s Reply: Prehabilitation Before Major Abdominal Surgery

Impacts of Preoperative Psoas Muscle Mass and Visceral Fat Area on Postoperative Short- and Long-Term Outcomes in Patients with Gastric Cancer

Short- and Long-Term Outcomes of Transabdominal Preperitoneal, Open Mesh Plug and Open Tissue Inguinal Hernia Repair

What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey